SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.

Recent health news highlights include high costs of weight-loss drugs like Wegovy, Septerna's strong Nasdaq debut, ...

Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.

Sanofi (SNY) has released an update. Sanofi reported a robust 15.7% growth in sales for Q3 2024, driven by strong performances in its vaccine ...

Sanofi (NASDAQ: SNY) Q3 2024 Earnings Call Oct 25, 2024, 8:00 a.m. ET Welcome to the Q3 2024 conference call for investors ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

Recent developments in healthcare cover a broad spectrum of issues: an analysis reveals that weight-loss drugs like Wegovy do ...

Sanofi said it would also apply its mRNA vaccine platform – acquired along with Translate Bio earlier this year – to find other acne vaccine candidates that could start clinical trials in 2023.

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

Pakistan and Afghanistan reported wild poliovirus type 1 cases, and Chad, Niger, and Niger reported circulating ...

We’ve taken a look at what a vaccine actually is and how long it might take until we get one, and news outlets have been reporting on the progress research teams around the world are making.

Researchers found that a daptomycin-resistance mutation in vancomycin-resistant Enterococcus faecium is linked to use of ...